The Food and Drug Administration March 28 said it is revising the label for the antidepressant Celexa (citalopram) and its generic versions to include new warnings about potential heart risks, as well as new drug dosage and usage recommendations.
Citalopram at any dose is discouraged in patients with certain conditions because of the risk of changes in the heart’s electrical activity (prolongation of the QT interval of the electrocardiogram [ECG]), the agency said. However, because it may be important for some of those patients to use citalopram, the label has been changed to describe the particular caution needed when the ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.